[1] WANG M X, GAO H Z, LIN N F, et al. The antibiotic resistance and pathogenicity of a multidrug-resistant Elizabethkingia anophelis isolate[J]. Microbiologyopen, 2019, 8(11):e804. doi:  10.1002/mbo3.804
[2] ZAJMI A, TEO J. YEO C C. Epidemiology and Characteristics of Elizabethkingia spp[J]. Infections in Southeast Asia Microorganisms, 2022.10. 882.
[3] TEO J, TAN S Y, TAY M, et al. First case of E anophelis outbreak in an intensive-care unit[J]. Lancet, 2013, 382(9895):855-856.
[4] LAU S K, CHOW W N, FOO C H, et al. Elizabethkingia anophelis bacteremia is associated with clinically significant infections and high mortality[J]. Sci Rep, 2016, 6:26045. doi:  10.1038/srep26045
[5] Lin J N, Lai C H, Yang C H, et al. Elizabethkingia Infections in Humans: From Genomics to Clinics[J]. Microorganisms, 2019, 7(9): 295.
[6] PERRIN A, LARSONNEUR E, NICHOLSON A C, et al. Evolutionary dynamics and genomic features of the Elizabethkingia anophelis 2015 to 2016 Wisconsin outbreak strain[J]. Nat Commun, 2017, 8:15483. doi:  10.1038/ncomms15483
[7] 刘喆, 王丽凤. 脑膜败血伊丽莎白菌耐药性及同源性分析[J]. 解放军医学院学报, 2020, 41(3):289-293.
[8] 常彦斌. 按蚊伊丽莎白菌菌种鉴定、感染临床特征以及耐药机制的实验研究[D]. 重庆: 重庆医科大学, 2022.
[9] CHENG Y H, PERNG C L, JIAN M J, et al. Multicentre study evaluating matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of clinically isolated Elizabethkingia species and analysis of antimicrobial susceptibility[J]. Clin Microbiol Infect, 2019, 25(3):340-345. doi:  10.1016/j.cmi.2018.04.015
[10] BARBOUR A, SCHMIDT S, MA B, et al. Clinical Pharmacokinetics and Pharmacodynamics of Tigecycline[J]. Clin Pharmacokinet, 2009,48(9): 575-584.
[11] RATNER H. Flavobacterium meningosepticum[J]. Infect Control, 1984, 5(5):237-239. doi:  10.1017/S0195941700060197
[12] FRANK T, GODY J C, NGUYEN L B, et al. First case of Elizabethkingia anophelis meningitis in the Central African Republic[J]. Lancet, 2013, 381(9880):1876. doi:  10.1016/S0140-6736(13)60318-9
[13] LIN J N, LAI C H, HUANG Y H, et al. Antimicrobial effects of minocycline, tigecycline, ciprofloxacin, and levofloxacin against Elizabethkingia anophelis using in vitro time-kill assays and in vivo zebrafish animal models[J]. Antibiotics, 2021, 10(3):285. doi:  10.3390/antibiotics10030285
[14] SOUKUP P, FAUST AC, EDPUGANT V, et al. Steady-state ceftazidime-avibactam serum concentrations and dosing recommendations in a critically ill patient being treated for Pseudomonas aeruginosa pneumonia and undergoing continuous venovenous hemodiafiltration[J]. Pharmacotherapy, 2019, 39(12):1216-1222. doi:  10.1002/phar.2338
[15] MAZUSKI J E, GASINK L B, ARMSTRONG J, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program[J]. Clin Infect Dis, 2016, 62(11):1380-1389. doi:  10.1093/cid/ciw133
[16] 余应嘉,叶淑芳,梁美芳.基于PK/PD模型结合蒙特卡洛模拟评价3种抗菌药物对铜绿假单胞菌感染延长输注给药方案[J].中国医院药学杂志,2022,42(4):373-377.